Back to News
Market Impact: 0.28
Nutromics receives FDA Breakthrough Device Designation
Source: Business Wire
Healthcare & BiotechProduct LaunchesRegulation & LegislationTechnology & Innovation
Nutromics received FDA Breakthrough Device Designation for its first product in development, a wearable device for vancomycin therapeutic drug monitoring (TDM). The designation may accelerate regulatory engagement and development of the monitoring technology, but the announcement provides no commercialization timeline or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Nvidia in talks to invest up to $10 billion in Anthropic IPO
- AnaptysBio earnings missed by $0.34, revenue fell short of estimates
- UBS sees Chinese carmakers reach 37% globally by 2030
- Exclusive-Nvidia in talks to invest in Anthropic’s mega IPO, sources say
- Trump says he’s open to Chinese automakers building cars in the U.S.
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying